Eli Lilly's Stock Spikes, Yet Team Jim Cramer Holds Back On Recommending Immediate Buying: 'Wait For A Pullback'

Jim Cramer does not recommend investors to buy Eli Lilly LLY stocks yet, despite the recent jump, CNBC reports.

Responding to an email query, Cramer mentioned a new 12-month price target of $600 for Eli Lilly.

Despite the promising outlook, the rapid ascent of Eli Lilly’s stock has led to caution. The recommendation is to wait for a pullback before making a purchase, emphasizing the importance of not buying a full position all at once. The long-term potential of Mounjaro is also highlighted, as Eli Lilly explores its use for conditions beyond diabetes and obesity.

“As much as we like the long-term story, we just aren't comfortable recommending a stock that has had the quick move that Eli Lilly has in recent weeks. We tend to view parabolic moves as an opportunity to book profits — not a chance to chase a move up,” Cramer’s team stated.

As of the latest update, Eli Lilly’s stock is priced at around $528, indicating a potential 14% increase to reach the new target. The revised price target is influenced by the company’s recent earnings report and its position as a leading growth story in large-cap pharma. This growth is attributed to the potential of diabetes treatment Mounjaro and Alzheimer's drug donanemab. The company’s valuation at the $600 target is based on 48 times the 2024 earnings estimates of $12.53 per share.

Image by Scott Beale on Flickr

Read Next: This Is What Whales Are Betting On Eli Lilly


Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsMarketsAnalyst RatingsMediaTrading Ideaseli lillyMounjaroJim Cramer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!